Pure Global
NCT06320418

The Epigenetic Regulatory Role of P-element Induced Wimpy Testis (Piwi) Interacting RNA-823 (piR-823) in Ovarian Cancer Progression

The Epigenetic Regulatory Role of P-element Induced Wimpy Testis (Piwi) Interacting RNA-
Ain Shams University·ClinicalTrials.govRecruitment Completed
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Ovarian Cancer
Study type
Observational
Sponsor & location
Primary sponsor
Ain Shams University
Location
Cairo, Egypt
Timeline & enrollment
Phase
N/A
Start date
Jun 15, 2022
End date
Jun 01, 2024
Enrollment
56 participants
Primary outcome

Association of piR-823 expression with ovarian cancer progression

Summary

Ovarian cancer (OC) has one of the highest mortality rates for female malignant tumors,
 attributed to advanced cancer stages upon diagnosis as well as a high recurrence rate.
 Piwi-interacting RNA-823 (piR-823) is a single-stranded non-protein coding RNA (ncRNA) star
 molecule in epigenetics research. Extensive cellular regulatory functions and aberrant
 expression of piR-823 have been implicated in carcinogenesis. Therefore, the findings of
 piwi-ncRNA dysregulated-expression in OC Egyptian female patients' cohort could be employed
 as a potential novel mechanism for OC precision, a step toward ncRNA-precision

ICD-10 classifications
Malignant neoplasm of ovarySecondary malignant neoplasm of ovaryBenign neoplasm of ovaryOvarian pregnancyOvarian dysfunction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06320418
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06320418 through Pure Global AI's free database. This phase not specified trial is sponsored by Ain Shams University and is currently Recruitment Completed. The study focuses on Ovarian Cancer. Target enrollment is 56 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.